| Trial ID: | L5006 |
| Source ID: | NCT01350102
|
| Associated Drug: |
Bacitracin
|
| Title: |
The Relationship of Hemoglobin A1c and Diabetic Wound Healing
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01350102/results
|
| Conditions: |
Diabetes, Type 1|Diabetes, Type 2|Foot Ulcer, Diabetic
|
| Interventions: |
DRUG: Bacitracin|DRUG: AmeriGel®|DIETARY_SUPPLEMENT: Vitamin C
|
| Outcome Measures: |
Primary: Hgb A1c Level, Hgb A1c measures the average blood glucose over three months (% of hemoglobin). All subjects will be asked to get their hemoglobin A1c level at the beginning of the study and every three months for as long as they participate in the study., Patients are assessed every 3 months from enrollment through end of study participation, which may be 6 months | Secondary: Length of Time for Wound Closure, Length of time for wound closure will be measured in days, Patients are assessed every other week (bi-weekly) until 100% wound healing is achieved, which may take up to 6 months|Wound Area Measurements, Wound area measurements in length, width, and depth throughout the course of the study(measured in cm)., Patients are assessed every other week (bi-weekly) until 100% wound healing is achieved, which may take up to 6 months
|
| Sponsor/Collaborators: |
Sponsor: Susan Hassenbein
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
2
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2012-02
|
| Completion Date: |
2014-03
|
| Results First Posted: |
2017-12-12
|
| Last Update Posted: |
2017-12-12
|
| Locations: |
Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, 17033, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01350102
|
